Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RTX vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RTX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

RTX Overall Winner 6-Pillar Tally: RTX 4 – 2 CRMD Matrix Metrics: RTX 5 – 4 CRMD

As of Nov 16, 2026, RTX Corporation (RTX) is the stronger overall head-to-head candidate over CorMedix Inc. (CRMD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RTX carries a Unified Composite Score of 53.4/100 (HOLD) at $194.95 (24.5x Forward P/E, 13.1% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).

  • Technical & Structure Timing Caution: RTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RTX vs CRMD
RTX NYSE Head-to-Head Winner
RTX Corporation
Aircraft Engines & Engine Parts
$194.95
-1.83% 1D
Market Cap $267.7B
TTM Revenue $96.0B
Forward P/E 24.5x
Beta / 30D Vol 0.28β · 29% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 44.0 Fund 45.0 Flow 55.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $196.80 · SMA50: $192.72
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11

6-Pillar Scorecard Institutional Category Breakdown (RTX 4 – 2 CRMD)

Columns: Metric · RTX · CRMD
1. Valuation Multiples RTX
Forward P/E 24.5x 49.0x
Trailing P/E 32.2x 2.4x
PEG Ratio 2.15x 3.79x
EV / Revenue 3.1x N/M
2. Growth & Scale RTX
Revenue Growth (YoY) +11.1% -47.7%
Earnings Growth (YoY) +34.0% +6.7%
TTM Revenue (USD) $96.0B $1.05B
Market Cap $267.7B $384.7M
3. Profitability & Quality CRMD
Gross Margin 21.1% 87.4%
Operating Margin 13.1% 41.0%
Net Profit Margin 8.8% 15.5%
Return on Equity (ROE) 12.8% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $9.13B $785M
Cash Flow Margin 9.5% 74.6%
Net Cash / Leverage $29.7B Net Debt (0.56x D/E) $535M Net Cash
Dividend Yield 1.40% None (0.00%)
5. Options & Positioning RTX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 49.8% (67th %ile) 56.3% (25th %ile)
Put/Call OI Skew 0.73x (Call-Skewed) 0.69x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat RTX
OpEx & R&D Intensity 8.0% of Rev ($7.68B) 46.4% of Rev ($488M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat High-Margin Pricing Power Moat
Supply-Chain Role Aerospace & Defense Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RTX (5) vs CRMD (4)
Institutional Metric RTX CRMD Criterion Row Edge
Market Capitalization
Scale
$267.7B $384.7M Larger Scale RTX
Trailing P/E Ratio
Valuation
32.2x 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
24.5x 49.0x Lower Multiple RTX
Revenue Growth (YoY)
Growth
+11.1% -47.7% Higher Growth RTX
Operating Margin (TTM)
Profitability
13.1% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
8.8% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
12.8% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
47% ($167–$227) 3% ($5–$13) Stronger Trend RTX
Beta / 30D Volatility
Risk Regime
0.28β · 29% Vol 1.20β · 107% Vol Lower Realized Risk RTX
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 53.2 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$96.0B $1.05B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.1% 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.15x PEG · 3.1x EV/Rev 3.79x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$9.13B ($29.7B Net Debt (0.56x D/E)) $785M ($535M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RTX +32.83 pp
RTX: +0.53% · CRMD: -32.3%
3M Horizon RTX +26.3 pp
RTX: -13.54% · CRMD: -39.84%
6M Horizon RTX +48.66 pp
RTX: +10.8% · CRMD: -37.86%
1Y Horizon RTX +68.23 pp
RTX: +12.07% · CRMD: -56.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RTX Revenue CRMD Revenue RTX Op. Margin CRMD Op. Margin Margin Leader
FY2018 $34.7B $0M 8.3% -6250.4% RTX
FY2019 $45.4B $0M 10.8% -7416.3% RTX
FY2020 $56.6B $0M -3.3% -11378.4% RTX
FY2021 $64.4B $0M 8.0% -15417.5% RTX
FY2022 $67.1B $0M 8.2% -46819.9% RTX
FY2023 $68.9B N/A 5.2% N/A RTX
FY2024 $80.7B $40M 8.1% -51.4% RTX
FY2025 $88.6B $310M 10.5% 48.2% CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RTX CONSOLIDATION
69d in phase · OBV NEUTRAL
Current IV 49.8%
IV Percentile 67th %ile
Put/Call OI Skew 0.73x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RTX Moat Profile Concentrated Oligopoly Moat
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $267.7B market capitalization and 13.1% operating margin.
OpEx & R&D Reinvestment 8.0% of Rev ($7.68B)
90D Engineering Disclosures 0 Published · Drone Autonomy / Counter-UAS
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published

Investor FAQ RTX vs CRMD Key Questions & Quantitative Answers

As of Nov 16, 2026, RTX Corporation (RTX) is the stronger overall head-to-head candidate over CorMedix Inc. (CRMD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RTX carries a Unified Composite Score of 53.4/100 (HOLD) at $194.95 (24.5x Forward P/E, 13.1% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Technical & Structure Timing Caution: RTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RTX leads the Growth & Scale pillar: RTX posts +11.1% YoY revenue growth and +34.0% YoY earnings growth on $96.0B TTM revenue (21.1% gross margin, 13.1% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RTX cumulative revenue shifted +155.3% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, RTX deploys 8.0% of Rev ($7.68B) (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.

RTX screens cheaper on headline valuation multiples. RTX trades at 24.5x Forward P/E, 32.2x Trailing P/E, 2.15x PEG, and 3.1x EV/Revenue (9.5% FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RTX (12.8% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RTX carries 49.8% implied volatility (67th %ile, Elevated (60th–80th %ile)), a 0.73x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 29% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.